Physician profile
Raed Odeh
NPI 1386263127
$19,007.05
in general payments reported to CMS, 2019-2025
15 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,363 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,015 · Food and Beverage: $6,898 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,680 · Travel and Lodging: $1,304 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,015.00 |
| Food and Beverage | $6,898.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,680.00 |
| Travel and Lodging | $1,304.47 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13,413.83 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,167.18 | 2024-2025 | Caplyta |
| Alkermes, INC. | $1,098.00 | 2024-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $917.41 | 2025 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $446.92 | 2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $413.00 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $324.50 | 2024-2025 | Fanapt |
| Abbvie INC. | $281.93 | 2025 | |
| Neurocrine Biosciences, INC. | $263.93 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $263.65 | 2024-2025 | Auvelity |
| Lundbeck LLC | $224.92 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Indivior INC. | $112.43 | 2024 | Perseris |
| Corium, LLC | $34.01 | 2025 | Azstarys |
| Bausch Health US, LLC | $28.57 | 2025 | Wellbutrin, Aplenzin |
| Collegium Pharmaceutical, INC. | $16.77 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raed Odeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.